Mystic Pharmaceuticals has announced that it has received a notice of allowance from the China Patent Office for a patent application titled “Deep Draw Container Forming Method” (invention number ZL200880106965.1). The company also said that it received a notice of allowance for an application titled “Combination Unit Dose Dispensing Container” (application number … [Read more...] about Mystic gets additional patents for intranasal technology
News
Malvern Instruments acquires NanoSight
Particle characterization company Malvern Instruments has announced its acquisition of UK-based nanoparticle characterization specialist NanoSight. NanoSight's instruments can analyze particle size, concentration, zeta potential, and aggregation of nanoparticles. Malvern Instruments Managing Director Paul Walker comented, “NanoSight is a real entrepreneurial … [Read more...] about Malvern Instruments acquires NanoSight
Transcept licenses intranasal DHE
Transcept Pharmaceuticals has acquired global development and commercialization rights to Shin Nippon Biomedical Laboratories' TO-2070 dihydroergotamine (DHE) nasal powder for the treatment of migraine, the companies announced. Transcept will pay $1 million up front plus development milestones totaling $6.5 million, commercialization milestones of up to $35 million, … [Read more...] about Transcept licenses intranasal DHE
Positive results in artificial pancreas plus inhaled insulin study
Diabetes research organization JDRF, along with Sansum Diabetes Research Institute, and the College of Engineering at University of California, Santa Barbara (UCSB) have announced positive results from a trial of an artificial pancreas used in conjunction with inhaled insulin taken at mealtimes. In 2010, MannKind Corporation announced that it would provide Afrezza … [Read more...] about Positive results in artificial pancreas plus inhaled insulin study
European approval for Ultibro Breezhaler
Just days after its approval in Japan, Novartis has announced that the Ultibro Breezhaler indacaterol/glycopyrronium (QVA149) DPI has been approved in Europe for the treatment of COPD. The approval triggers $10 million milestone payments to Sosei and Vectura. Novartis Pharmaceuticals Division Head David Epstein commented, "We are very pleased that the European … [Read more...] about European approval for Ultibro Breezhaler
Positive opinion on Fluenz Tetra from CHMP
According to AstraZeneca, it has received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) for its Fluenz Tetra intranasal four-strain live attenuated influenza vaccine developed by its MedImmune subsidiary. Fluenz Tetra includes two strains of influenza A and two strains of influenza B. If approved, the vaccine would replace … [Read more...] about Positive opinion on Fluenz Tetra from CHMP
Avanir publishes data on intranasal sumatriptan
Avanir Pharmaceuticals has published results of a pharmacokinetic study of its AVP-825 intranasal sumatriptan powder for the treatment of acute migraine. Avanir licensed AVP-825 from OptiNose in July 2013, and the powder is delivered using the OptiNose breath-activated intranasal device. The study, published in Headache, compared AVP-825 to liquid nasal spray, oral … [Read more...] about Avanir publishes data on intranasal sumatriptan
Ultibro inhalation capsules approved in Japan
Sosei Group and Vectura have announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Ultibro glycopyrronium/indacaterol inhalation capsules, which are delivered using the Breezhaler DPI, for treatment of COPD. Ultibro, also known as QVA149, was developed by Novartis, which filed the Japanese marketing application in November 2012. … [Read more...] about Ultibro inhalation capsules approved in Japan
Relvar Ellipta recommended for approval by CHMP, approved in Japan
GlaxoSmithKline and Theravance have announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the Relvar Ellipta fluticasone furoate/vilanterol (FF/VI) DPI for the treatment of asthma for patients who require a combination inhaler for adequate control and for the treatment of COPD patients with … [Read more...] about Relvar Ellipta recommended for approval by CHMP, approved in Japan
Mundipharma launches Flutiform trial for COPD
A Phase 3 trial of Flutiform fluticasone propionate/formoterol fumarate MDI for the treatment of COPD has been initiated, according Mundipharma. The 52-week randomized, double-blind EFFECT study compare Flutiform 250/10 μg and Flutiform 125/5 μg with formoterol 12 μg. Flutiform is approved in Europe for the treatment of asthma; it is not approved for the treatment of … [Read more...] about Mundipharma launches Flutiform trial for COPD